Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript Summary
Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript Summary
A non-recurring non-cash charge of $2.8 million impacted gross margins significantly, lowering it to 0.9%. Excluding this charge, the adjusted gross margin would have been 29.8%.The following is a summary of the Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript:
以下是Alpha Teknova, Inc.（TKNO）2024年第三季度業績會議實錄摘要：
Financial Performance:
財務表現：
Alpha Teknova, Inc. reported a 17% increase in revenue from the previous year in Q3 of 2024, with total revenue reaching $9.6 million.
Despite implementing significant cost reductions, including lowering operating expenses by more than $9 million annually since the end of 2023, the company experienced a net loss of $7.6 million or $0.15 per share.
A non-recurring non-cash charge of $2.8 million impacted gross margins significantly, lowering it to 0.9%. Excluding this charge, the adjusted gross margin would have been 29.8%.
Alpha Teknova, Inc.報告稱，2024年第三季度收入比去年同期增長17%，總收入達到960萬美元。
儘管自2023年底以來實施了大幅降低營業費用超過900萬美元的重大成本削減措施，但公司經歷了760萬美元的淨損失，每股虧損0.15美元。
一筆280萬美元的非經常性非現金費用嚴重影響了毛利率，將其降低到0.9%。不計入此費用，調整後的毛利率將達到29.8%。
Business Progress:
業務進展：
Alpha Teknova saw strong sales in custom research and clinical-grade reagents to biopharma customers, contributing to their revenue growth.
The company's customer base in Lab Essentials and Clinical Solutions both saw an increase, indicating enhanced market outreach and service acceptance.
Teknova has adjusted its manufacturing and inventory management to better match current market conditions and demand forecasts.
Alpha Teknova在爲生物製藥客戶提供定製研究和臨床級試劑方面取得了強勁銷售，爲其收入增長做出了貢獻。
公司的實驗室必需品和臨床解決方案客戶群體都有所增加，表明市場拓展和服務接受度得到提升。
Teknova已調整其製造業和庫存管理，以更好地匹配當前的市場條件和需求預測。
Opportunities:
機會：
Expecting modest market growth in 2025, Alpha Teknova anticipates capitalizing on their diversified and growing client base in the biopharma sector.
Continued expansions in Clinical Solutions suggest potential future revenue growth as these products are both increasing in customer numbers and average revenue per client.
Alpha Teknova預計2025年市場將有適度增長，並期待在生物製藥板塊中實現利潤增長，該公司擁有多樣化且不斷增長的客戶群。
Clinical Solutions持續擴張表明潛在未來營業收入增長，因爲這些產品的客戶數量和平均客戶收入都在增加。
Risks:
風險：
The company experienced lower sales to large life science tools companies due to factors believed to be either timing related or account-specific, which highlights the risk of variability in major client orders.
A recent cancelation of a large Clinical Solutions order, expected for delivery in the fourth quarter, may affect short-term revenue projections.
由於被認爲是時間相關或與帳戶相關的因素，公司對大型生命科學工具公司的銷售下降，突顯了主要客戶訂單的風險變化。
最近取消了一個原定於第四季度交付的大型Clinical Solutions訂單，可能會影響短期營業收入預測。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
